Greifswald

• Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans … Recruiting
  2023-507879-21-00 4 2026-01-19 AML and MDS undergoing allogeneic Transplantation
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489 Recruiting
  2025-521155-23-00 4 2025-12-19 Pulmonary Arterial Hypertension
• Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc … Recruiting
  2022-500676-59-00 4 2025-12-18 EBV-positive nasopharyngeal carcinoma
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting
  2024-515682-34-00 5 2025-10-06 Chronic migraine
• A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting
  2024-515715-22-00 5 2025-10-06 Episodic migraine
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 High-grade B-cell lymphoma (HGBL)
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab … Recruiting
  2024-519827-16-00 5 2025-09-30 Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Recruiting
  2024-517529-26-00 5 2025-08-04 Chronic Inflammatory Demyelinating Polyneuropathy
• Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leu … Recruiting
  2023-509055-14-00 4 2025-06-17 myelodysplastic neoplasia (MDS)
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2024-517513-32-00 5 2025-05-16 Sjögren’s Syndrome
• Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi … Recruiting
  2023-508076-11-00 5 2025-04-01 Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma Recruiting
  2023-509673-22-00 9 2024-12-02 Neuroblastoma
• A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting
  2023-508191-11-00 5 2024-11-28 Systemic lupus erythematosus (SLE)
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Patient- and care-related benefits of amyloid PET imaging (ENABLE) Recruiting
  2023-503705-10-00 6 2024-08-19 Dementia in Pick disease
• Scabies therapy with two differently concentrated permethrin creams Recruiting
  2023-507925-41-00 5 2024-08-14 Scabies
• Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial Recruiting
  2024-516634-35-00 6 2024-02-01 Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
• Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in … Recruiting
  2023-504351-26-01 11 2023-12-06 Pulmonary arterial hypertension (group I)

Showing 25–48 of 122 trials